Expert consensus on treatment and management of tuberculosis-diabetes mellitus

doi:10.3969/j.issn.1000-6621.2021.01.004

Abstract

Abstract:

Tuberculosis (TB) and diabetes mellitus (DM) are both frequently-occurring clinical diseases and global pandemics. The two can coexist and influence each other. DM increases the risk of active TB, and TB may provoke hyperglycemia. The double burden of TB and DM has become a major public health problem. Therefore, it is necessary to manage the two diseases jointly. This consensus focuses on the pandemics, two-way screening, pathogenesis, clinical features, diagnosis, treatment and management of comorbidity of TB-DM, providing guidance to health care workers.

Key words: Tuberculosis, Diabetes mellitus, Comorbidity, Combined modality therapy, Disease management, Consensus development conferences as topic

National Clinical Research Center for Infectious Disease/, The Third People’s Hospital of Shenzhen, National Clinical Research Center for Metabolic Disease, The Second Xiangya Hospital of Central South University, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on treatment and management of tuberculosis-diabetes mellitus[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 12-22. doi: 10.3969/j.issn.1000-6621.2021.01.004

Figures/Tables 4

药物名称	药理作用	同RFP的相互作用	建议的应对措施
二甲双胍	抑制肝脏血糖的产生、抑制肠道葡萄糖吸收、增加胰岛素敏感度	增加有机阳离子转运蛋白(OCT1)的表达和肝脏对二甲双胍的吸收;同时给予二甲双胍和利福平可增加二甲双胍的血药浓度,增强二甲双胍的降糖作用	当利福平加入二甲双胍治疗时,应密切监测血糖水平,观察同时服用二甲双胍和利福平患者的低血糖症状和体征
磺脲类	促进胰岛素分泌	磺脲类药物是CYP2C9的底物,与CYP2C9诱导物利福平同时使用可能会降低其血药浓度,增加高血糖的风险	增加血糖监测的频率、考虑调整药品剂量或选择其他降糖药物
格列奈类	促进胰岛素分泌	利福平诱导CYP3A4酶,降低了格列奈类药品的血药浓度	增加血糖监测的频率,考虑调整药品剂量或选择其他降糖药物
噻唑烷二酮类	增加胰岛素的敏感性,降低肝脏葡萄糖生成	利福平作为CYP2C8的诱导剂,能降低吡格列酮和罗格列酮的血药浓度	增加血糖监测的频率,考虑调整药品剂量或选择其他降糖药物
糖苷酶抑制剂类	延缓肠道葡萄糖的吸收	尚无报道	无特殊措施
DPP-IV抑制剂	促进胰岛素分泌	利福平通过诱导CYP3A4和三磷酸腺苷结合盒转运体(ATP-binding cassette transporters, ABC转运体)(P糖蛋白),可降低利格列汀、沙格列汀的血药浓度	增加血糖监测的频率,考虑调整药品剂量或选择其他降糖药物(推荐将利格列汀换为同类别的其他药品)
SGLT-2抑制剂	促进尿糖排泄	利福平诱导UGT1A9, UGT2B4使得卡格列净暴露降低而降低疗效	密切监测,并结合eGFR水平调整药品剂量。当eGFR<60ml·min^-1·(1.73m²)^-1时,应该考虑换药
GLP-1受体激动剂	结合GLP-1受体,刺激胰岛素分泌	GLP-1RA和利福平合用时,由于前者可延迟胃排空而可能减缓利福平的吸收	密切监测,如果需要同时使用,可以在GLP-1RA注射前1 h给予口服利福平,以达到有效的血药浓度

References 59

[1]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019,7(4):e448-460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X URL pmid: 30819531
[2]	毛毅, 范琳, 刘勇. 肺结核并发糖尿病的诊治研究进展. 中国防痨杂志, 2019,41(12):1325-1329. doi: 10.3969/j.issn.1000-6621.2019.12.015.
[3]	Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract, 2019,157:107843. doi: 10.1016/j.diabres.2019.107843. doi: 10.1016/j.diabres.2019.107843 URL pmid: 31518657
[4]	Odone A, Houben RM, White RG, et al. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol, 2014,2(9):754-764. doi: 10.1016/S2213-8587(14)70164-0 URL pmid: 25194888
[5]	Workneh MH, Bjune GA, Yimer SA. Prevalence and associa-ted factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One, 2017,12(4):e0175925. doi: 10.1371/journal.pone.0175925. doi: 10.1371/journal.pone.0175925 URL pmid: 28430796
[6]	Lin Y, Harries AD, Kumar AMV, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, World Diabetes Foundation, 2019.
[7]	Al-Rifai RH, Pearson F, Critchley JA, et al. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One, 2017,12(11):e0187967. doi: 10.1371/journal.pone.0187967. doi: 10.1371/journal.pone.0187967 URL pmid: 29161276
[8]	Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology, 2017,152(1):13-24. doi: 10.1111/imm.12762. doi: 10.1111/imm.12762 URL pmid: 28543817
[9]	Ayelign B, Negash M, Genetu M, et al. Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis. J Immunol Res, 2019,2019:6196532. doi: 10.1155/2019/6196532. doi: 10.1155/2019/6196532 URL pmid: 31583258
[10]	Ferlita S, Yegiazaryan A, Noori N, et al. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J Clin Med, 2019,8(12):2219. doi: 10.3390/jcm8122219. doi: 10.3390/jcm8122219 URL
[11]	Eckold C, Kumar V, Weiner Rd J, et al. Impact of intermediate hyperglycaemia as well as diabetes on immune dysfunction in tuberculosis. Clin Infect Dis, 2020: ciaa751. doi: 10.1093/cid/ciaa751. Epub ahead of print.
[12]	Duffy FJ, Weiner J 3rd, Hansen S, et al. Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Front Immunol, 2019,10:527. doi: 10.3389/fimmu.2019.00527. doi: 10.3389/fimmu.2019.00527 URL pmid: 30967866
[13]	Wang Q, Ma A, Schouten EG, et al. A double burden of tuberculosis and diabetes mellitus and the possible role of vitamin D deficiency. Clin Nutr, 2020: S0261-5614(20)30456-8. doi: 10.1016/j.clnu.2020.08.040. Epub ahead of print. doi: 10.1016/j.clnu.2020.12.011 URL pmid: 33358552
[14]	Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011,9:81. doi: 10.1186/1741-7015-9-81. doi: 10.1186/1741-7015-9-81 URL pmid: 21722362
[15]	Harries AD, Kumar AM, Satyanarayana S, et al. Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis, 2015,19(8):879-886. doi: 10.5588/ijtld.15.0069. doi: 10.5588/ijtld.15.0069 URL pmid: 26162352
[16]	Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle, 1990,71(2):135-138. doi: 10.1016/0041-3879(90)90010-6. doi: 10.1016/0041-3879(90)90010-6 URL pmid: 2219464
[17]	Lin Y, Yuan Y, Zhao X, et al. The change in blood glucose levels in tuberculosis patients before and during anti-tuberculosis treatment in China. Glob Health Action, 2017,10(1):1289737. doi: 10.1080/16549716.2017.1289737. doi: 10.1080/16549716.2017.1289737 URL pmid: 28470109
[18]	Lin Y, Li L, Mi F, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health, 2012,17(10):1302-1308. doi: 10.1111/j.1365-3156.2012.03069.x. doi: 10.1111/j.1365-3156.2012.03069.x URL
[19]	Lin Y, Innes A, Xu L, et al. Screening of patients with diabetes mellitus for tuberculosis in community health settings in China. Trop Med Int Health, 2015,20(8):1073-1080. doi: 10.1111/tmi.12519. doi: 10.1111/tmi.12519 URL pmid: 25877338
[20]	姜辉, 刘玉琴. 结核病合并糖尿病的流行现状及其防控. 生物技术进展, 2017,7(1):25-29. doi: 10.3969/j.issn.2095-2341.2017.01.05.
[21]	Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis, 2007,45(4):428-435. doi: 10.1086/519841. doi: 10.1086/519841 URL pmid: 17638189
[22]	Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract, 2014,106(2):191-199. doi: 10.1016/j.diabres.2014.06.011. doi: 10.1016/j.diabres.2014.06.011 URL pmid: 25082309
[23]	Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol, 2012,7:353-384. doi: 10.1146/annurev-pathol-011811-132458. doi: 10.1146/annurev-pathol-011811-132458 URL pmid: 22054143
[24]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
[25]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09.
[26]	Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. Diabetes Res Clin Pract, 1999,44(1):21-26. doi: 10.1016/s0168-8227(99)00008-x. doi: 10.1016/s0168-8227(99)00008-x URL pmid: 10414936
[27]	World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation. Geneva: World Health Organization, 2011.
[28]	World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, 2017.
[29]	高静韬, 王笑春, 付亮, 等. 药物敏感性肺结核治疗和患者关怀指南——2017年更新版. 国际呼吸杂志, 2018,38(3):161-168. doi: 10.3760/cma.j.issn.1673-436X.2018.03.001.
[30]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment- drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[31]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006.
[32]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
[33]	李亮, 李琦, 许绍发, 等. 结核病治疗学. 北京: 人民卫生出版社, 2013: 221-336.
[34]	中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 中国儿童1型糖尿病标准化诊断与治疗专家共识(2020版). 中华儿科杂志, 2020,58(6):447-454. doi: 10.3760/cma.j.cn112140-20200221-00124.
[35]	中华医学会糖尿病学分会. 中国1型糖尿病胰岛素治疗指南. 中华糖尿病杂志, 2016,8(10):591-597. doi: 10.3760/cma.j.issn.1674-5809.2016.10.005.
[36]	Lin KH, Luo CW, Chen SP, et al. α-Glucosidase Inhibitor Can Effectively Inhibit the Risk of Tuberculosis in Patients with Diabetes: A Nested Case-Control Study. Biomed Res Int, 2020,2020:8085106. doi: 10.1155/2020/8085106. doi: 10.1155/2020/8085106 URL pmid: 32509871
[37]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版). 中华糖尿病杂志, 2018,10(1):4-67. doi: 10.3760/cma.j.issn.1674-5809.2018.01.002.
[38]	Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015,147(2):520-528. doi: 10.1378/chest.14-0918. doi: 10.1378/chest.14-0918 URL pmid: 25255302
[39]	Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc, 2011,110(6):372-381. doi: 10.1016/S0929-6646(11)60055-7.
[40]	Atif M, Sulaiman SA, Shafie AA, et al. Duration of treatment in pulmonary tuberculosis: are international guidelines on the management of tuberculosis missing something? Public Health, 2015,129(6):777-782. doi: 10.1016/j.puhe.2015.04.010. doi: 10.1016/j.puhe.2015.04.010 URL pmid: 25999175
[41]	Wu Z, Guo J, Huang Y, et al. Diabetes mellitus in patients with pulmonary tuberculosis in an aging population in Shanghai, China: Prevalence, clinical characteristics and outcomes. J Diabetes Complications, 2016,30(2):237-241. doi: 10.1016/j.jdiacomp.2015.11.014. doi: 10.1016/j.jdiacomp.2015.11.014 URL pmid: 26684166
[42]	唐神结, 高文. 临床结核病学. 2版. 北京: 人民卫生出版社, 2019: 936-948.
[43]	吕亚男, 宫媛媛. 乙胺丁醇相关视神经病变. 国际眼科杂志, 2019,19(2):240-243. doi: 10.3980/j.issn.1672-5123.2019.2.12.
[44]	Castro AT, Mendes M, Freitas S, et al. Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol (2006), 2015,21(3):144-150. doi: 10.1016/j.rppnen.2014.08.004.
[45]	Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol, 2014 , 2(9):740-753. doi: 10.1016/S2213-8587(14)70110-X. doi: 10.1016/S2213-8587(14)70110-X URL pmid: 25194887
[46]	中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019,42(5):343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007.
[47]	桂徐蔚, 沙巍. 肺结核合并糖尿病研究进展. 中国实用内科杂志, 2015,35(8):657-660. doi: 10.7504/nk2015070107.
[48]	母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2016年版). 中国糖尿病杂志, 2016,24(10):871-884. doi: 10.3969/j.issn.1006-6187.2016.10.02.
[49]	《中国防痨杂志》编委会, 中国医疗保健国际交流促进会结核病防治分会全国耐药结核病协作组. 耐药结核病化疗过程中药品不良反应处理的专家共识. 中国防痨杂志, 2019,41(6):591-603. doi: 10.3969/j.issn.1000-6621.2019.06.003.
[50]	Lönnroth K, Williams BG, Cegielski P, et al. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol, 2010,39(1):149-155. doi: 10.1093/ije/dyp308. doi: 10.1093/ije/dyp308 URL pmid: 19820104
[51]	中华医学会结核病学分会重症专业委员会. 结核病营养治疗专家共识. 中华结核和呼吸杂志, 2020,43(1):17-26. doi: 10.3760/cma.j.issn.1001-0939.2020.01.006.
[52]	中华医学会糖尿病学分会, 中国医师协会营养医师专业委员会. 中国糖尿病医学营养治疗指南(2013). 中华糖尿病杂志, 2015,7(2):73-88. doi: 10.3760/cma.j.issn.1674-5809.2015.02.004.
[53]	中华医学会内分泌学分会. 中国2型糖尿病合并肥胖综合管理专家共识. 中华内分泌代谢杂志, 2016,32(8):623-627. doi: 10.3760/cma.j.issn.1000-6699.2016.08.001.
[54]	中华人民共和国国家卫生与计划生育委员会办公厅. 肺结核患者健康管理服务规范.国卫办基层函〔2015〕880号. 2015-10-27.
[55]	中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识. 中华内分泌代谢杂志, 2017,33(1):1-10. doi: 10.3760/cma.j.issn.1000-6699.2017.01.001.
[56]	中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版). 中华糖尿病杂志, 2015,7(10):603-613. doi: 10.3760/cma.j.issn.1674-5809.2015.10.004.
[57]	American Diabetes Association. 6. Glycemic Targets: Stan-dards of Medical Care in Diabetesd—2020. Diabetes Care, 2020,43 Suppl 1: S66-76. doi: 10.2337/dc20-S006. doi: 10.2337/dc20-S006 URL pmid: 31862749
[58]	中华医学会糖尿病学分会. 中国高血糖危象诊断与治疗指南. 中华糖尿病杂志, 2013,5(8):449-461. doi: 10.3760/cma.j.issn.1674-5809.2013.08.001.
[59]	Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systema-tic review and meta-analysis. Int J Tuberc Lung Dis, 2019,23(7):783-796. doi: 10.5588/ijtld.18.0433. doi: 10.5588/ijtld.18.0433 URL pmid: 31439109

典型糖尿病症状	静脉血浆葡萄糖水平
多尿、多饮、多食、	加上: 随机血糖≥11.1mmol/L
体质量减轻	或加上:空腹血糖≥7.0mmol/L
	或加上:葡萄糖负荷后2h血糖≥11.1mmol/L
	或加上:糖化血红蛋白≥6.5%

临床类别	血糖控制目标
结核病治疗期间^[6,55]
一般情况下	HbA1c<7.0%,空腹4.4~7.0mmol/L,非空腹<10.0mmol/L
并发心脑血管疾病、心脑血管疾病高风险、高龄、结核病病情严重	HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹7.8~13.9mmol/L
非结核病治疗期间^[36,55]
年龄较小、病程较短、预期寿命较长、无并发症、未并发心血管疾病	HbA1c<6.5%,空腹4.4~6.1mmol/L,非空腹6.1~7.8mmol/L
大多数非妊娠成年患者	HbA1c<7.0%,空腹4.4~7.0mmol/L,非空腹<10.0mmol/L
高龄、低血糖发生风险较高且无法耐受低血糖、存在多器官功能不全、预期生存期低于5年、需重症监护	HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹7.8~13.9mmol/L